Recently, the market for the three leading series of products including penicillin, cephalosporin, and VC began to take a turn for the better, and the domestic pharmaceutical market gradually recovered. The city's backbone pharmaceutical companies took advantage of this favorable situation, from all aspects such as increasing sales efforts, tapping potential and reducing consumption, technological innovation, and improving profit levels, and strive to draw a successful conclusion for 2006.
According to reports, as pharmaceutical products enter the sales season in the fourth quarter, some manufacturers are expecting stocking and exporting to increase, making the market of raw material medicine products promising, sales growth, output increase, and price increase. After the Indian side stopped its anti-monopoly investigation of penicillin in China, sales in the international market began to be smooth and penicillin prices rebounded. The sales price of other leading products in the city also rebounded. VC sales prices began to rise. These favorable factors will enable the city's pharmaceutical industry in the fourth quarter of production growth and efficiency indicators to steadily rise. In addition, the introduction of some industry policies has provided opportunities for the development of the pharmaceutical market, mainly including the tilting of national policies to community and rural health centers, the construction of rural “two networks†and the reform of the new rural cooperative medical system, and the rapid spread of urban medical insurance, and In the new round of drug price adjustment, the price of penicillin powder and other generic drugs has increased, which is a good thing for the Huayou Group and Shiyao Group that produce penicillin powder in our city. It is suitable for many low-price enterprises in our city. The wide variety of generic medicines provides a very favorable market opportunity.
According to the analysis of the provincial pharmaceutical industry, in the first half of this year, although the sales revenue of the domestic pharmaceutical industry increased significantly, the increase in profits was only 6.3%, which has fallen to the lowest point in history and is the second lowest in the country's 12 largest industrial sectors. In this context, several major pharmaceutical companies in the provincial capital, especially chemical and pharmaceutical companies, have not had a good day. Although sales revenue continues to grow, their profitability has dropped significantly. Therefore, seizing the favorable opportunity for the market to recover at the end of the year has become the key to reversing the year-round production and operating situation toward sound development.
Huayao New Drug Center is the first and only state-level engineering research center in Hebei Province since the founding of the People's Republic of China. At present, the center focuses on enhancing original innovation, integrated innovation, and the ability to absorb, re-innovate, and introduce new technologies. It has formed a complete set of technological innovation systems from product source development to pilot-to-industrialization.
At the same time, Huayin has increased the product registration certification, especially the registration of formulated products, implemented a diversification strategy for foreign trade exports, and actively explored potential markets such as Europe, the United States, and the Middle East. The export products have gradually achieved the transition from exporting raw materials to high value-added pharmaceutical raw materials and pharmaceutical preparations. At present, the export of pharmaceutical products has risen from the auxiliary status to the dominant position.
Another pharmaceutical giant, Shijiazhuang Group, has taken various measures to expand production and increase efficiency. In Sinopharm Group's Zhongrun Pharmaceutical Co., the leading product 6-APA has already achieved full-load production, and the production of penicillin industrial salt and 7-ACA has also gradually increased. In order to ensure the quality of hot-selling products, the company put forward quality assurance requirements on the product's color grade and moisture, reasonably arranged the drying time, and improved the product's excellent product rate.
On the one hand, Shijiazhuang Group's Weisheng Pharmaceutical Co., Ltd. has increased the promotion of deep-processed products, especially wet-process particles, in order to attract potential customers. At the same time, increase the market development of food additives, and promote the application of VC calcium, VC sodium, VC fine powder as preservatives and flour high-strength agents. On the other hand, efforts have been made to promote energy conservation and consumption reduction, and through the implementation of effective measures such as the "moving peaks and filling valleys" electricity consumption plan in power stations, the production cost of VC has been reduced by 5.92% compared with the same period of last year, which has enhanced the competitiveness of products.
As one of the leading companies in the “big infusion†field in China, Shijiazhuang Four Drugs has strengthened its infusion products while consolidating infusion products. At present, the product is in short supply, and the sales situation is gratifying. In the past two months, the company’s flagship products such as Yikangkang and Yilikang injections, azithromycin dispersible tablets, cephalexin capsules, arbidol hydrochloride capsules, toothachean, and periodontal products have steadily increased in sales volume. Gradually increased, including Yi Li Kang tablets, injections have exceeded the level of the same period last year.
With excellent modern Chinese medicine, Shenwei Pharmaceutical achieved good operating results in an overall unfavorable environment. Compared with the same period of last year, it maintained a sustained and stable growth and showed strong development momentum in the industry. At present, Shenwei Pharmaceutical continues to expand its sales channels, strengthen quality management, strictly manage raw and auxiliary materials procurement, production, and inspection, develop new varieties, expand competitive advantages, and strive to occupy the first place in current and future market competitions. machine.
The relevant person in charge of the Provincial Pharmaceutical Industry Association pointed out that after the rectification of the pharmaceutical industry, a considerable number of “small, scattered, chaotic†and “pharmaceutical speculation†companies will be cleared out of the pharmaceutical industry, and the industry's threshold will increase next year, which is currently vicious and unordered. The competition will also become orderly and standardized. Shijiazhuang powerful large enterprise groups will gain greater room for development.
According to reports, as pharmaceutical products enter the sales season in the fourth quarter, some manufacturers are expecting stocking and exporting to increase, making the market of raw material medicine products promising, sales growth, output increase, and price increase. After the Indian side stopped its anti-monopoly investigation of penicillin in China, sales in the international market began to be smooth and penicillin prices rebounded. The sales price of other leading products in the city also rebounded. VC sales prices began to rise. These favorable factors will enable the city's pharmaceutical industry in the fourth quarter of production growth and efficiency indicators to steadily rise. In addition, the introduction of some industry policies has provided opportunities for the development of the pharmaceutical market, mainly including the tilting of national policies to community and rural health centers, the construction of rural “two networks†and the reform of the new rural cooperative medical system, and the rapid spread of urban medical insurance, and In the new round of drug price adjustment, the price of penicillin powder and other generic drugs has increased, which is a good thing for the Huayou Group and Shiyao Group that produce penicillin powder in our city. It is suitable for many low-price enterprises in our city. The wide variety of generic medicines provides a very favorable market opportunity.
According to the analysis of the provincial pharmaceutical industry, in the first half of this year, although the sales revenue of the domestic pharmaceutical industry increased significantly, the increase in profits was only 6.3%, which has fallen to the lowest point in history and is the second lowest in the country's 12 largest industrial sectors. In this context, several major pharmaceutical companies in the provincial capital, especially chemical and pharmaceutical companies, have not had a good day. Although sales revenue continues to grow, their profitability has dropped significantly. Therefore, seizing the favorable opportunity for the market to recover at the end of the year has become the key to reversing the year-round production and operating situation toward sound development.
Huayao New Drug Center is the first and only state-level engineering research center in Hebei Province since the founding of the People's Republic of China. At present, the center focuses on enhancing original innovation, integrated innovation, and the ability to absorb, re-innovate, and introduce new technologies. It has formed a complete set of technological innovation systems from product source development to pilot-to-industrialization.
At the same time, Huayin has increased the product registration certification, especially the registration of formulated products, implemented a diversification strategy for foreign trade exports, and actively explored potential markets such as Europe, the United States, and the Middle East. The export products have gradually achieved the transition from exporting raw materials to high value-added pharmaceutical raw materials and pharmaceutical preparations. At present, the export of pharmaceutical products has risen from the auxiliary status to the dominant position.
Another pharmaceutical giant, Shijiazhuang Group, has taken various measures to expand production and increase efficiency. In Sinopharm Group's Zhongrun Pharmaceutical Co., the leading product 6-APA has already achieved full-load production, and the production of penicillin industrial salt and 7-ACA has also gradually increased. In order to ensure the quality of hot-selling products, the company put forward quality assurance requirements on the product's color grade and moisture, reasonably arranged the drying time, and improved the product's excellent product rate.
On the one hand, Shijiazhuang Group's Weisheng Pharmaceutical Co., Ltd. has increased the promotion of deep-processed products, especially wet-process particles, in order to attract potential customers. At the same time, increase the market development of food additives, and promote the application of VC calcium, VC sodium, VC fine powder as preservatives and flour high-strength agents. On the other hand, efforts have been made to promote energy conservation and consumption reduction, and through the implementation of effective measures such as the "moving peaks and filling valleys" electricity consumption plan in power stations, the production cost of VC has been reduced by 5.92% compared with the same period of last year, which has enhanced the competitiveness of products.
As one of the leading companies in the “big infusion†field in China, Shijiazhuang Four Drugs has strengthened its infusion products while consolidating infusion products. At present, the product is in short supply, and the sales situation is gratifying. In the past two months, the company’s flagship products such as Yikangkang and Yilikang injections, azithromycin dispersible tablets, cephalexin capsules, arbidol hydrochloride capsules, toothachean, and periodontal products have steadily increased in sales volume. Gradually increased, including Yi Li Kang tablets, injections have exceeded the level of the same period last year.
With excellent modern Chinese medicine, Shenwei Pharmaceutical achieved good operating results in an overall unfavorable environment. Compared with the same period of last year, it maintained a sustained and stable growth and showed strong development momentum in the industry. At present, Shenwei Pharmaceutical continues to expand its sales channels, strengthen quality management, strictly manage raw and auxiliary materials procurement, production, and inspection, develop new varieties, expand competitive advantages, and strive to occupy the first place in current and future market competitions. machine.
The relevant person in charge of the Provincial Pharmaceutical Industry Association pointed out that after the rectification of the pharmaceutical industry, a considerable number of “small, scattered, chaotic†and “pharmaceutical speculation†companies will be cleared out of the pharmaceutical industry, and the industry's threshold will increase next year, which is currently vicious and unordered. The competition will also become orderly and standardized. Shijiazhuang powerful large enterprise groups will gain greater room for development.
90W-9T High-matching Wheel Excavator
SD90W-9T is built by the R&D center of Shanding, which is intelligent, flexible, efficient, safe and reliable. It is in line with the new generation of ergonomic working environment and realizes the multi-functional excavator with one machine.
Hydraulic Wheel Excavator 9 Ton,9Ton Mini Bucket Wheel Excavator,Hydraulic Wheeled Excavator,Compact Wheeled Excavator
Shandong Davoo Machinery Co., Ltd. Trading Company , https://www.nbsddigger.com